Page 43, please delete the paragraph beginning at line 11, and insert the following paragraph therefor:

Plasmid pUT18 (3023-bp) is a derivative of the high copy number vector pUC19 (expressing an ampicillin resistance selectable marker and compatible with pT25 or pKT25) that encodes the T18 fragment (amino acids 225 to 399 of CyaA). In a first step, we constructed plasmid pUC19L by inserting a 23-bp double-stranded oligonucleotide (5'-AATTCATCGATATAACTAAGTAA-3' (SEQ ID No.: 1)) and its complementary sequence) between the *Eco*RI and *Nde*I sites of pUC19. Then, a 534-bp fragment harboring the T18 open reading frame was amplified by PCR (using appropriate primers and pT18 as target DNA) and cloned into pUC19L digested by *Eco*RI and *Cla*I (the appropriate restriction sites were included into the PCR primers). In the resulting plasmid, pUT18, the T18 open reading frame is fused in frame downstream of the multicloning site of pUC19. This plasmid is designed to create chimeric proteins in which a heterologous polypeptide is fused to the N-terminal end of T18 (see map).

Please insert the attached Sequence Listing (pages 1-4) as pages 62-65 and renumber the application accordingly.

IN THE CLAIMS:

Please cancel claims 1-9, 24, and 39-45 without prejudice or disclaimer. Please amend claims 10-22 and 25-38 and add new claims 45-48, as follows:

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408 4000